Ono Pharmaceutical Co., Ltd. ADR (OPHLY)

Overview

Ono Pharmaceutical Co., Ltd., a venerable entity in the pharmaceutical industry, was founded in 1717 and has its headquarters in Osaka, Japan. With a global presence, the company, along with its subsidiaries, is engaged in the production, procurement, and commercialization of pharmaceuticals and diagnostic reagents. Ono Pharmaceutical is noted for its influential collaborations with entities like Adimab, LLC, Turbine Ltd., Harvard University, and Sibylla Biotech, focusing on the discovery and development of novel antibody drugs, oncology targets, therapeutic targets, and drugs for central nervous system disorders. The company's endeavors span a wide spectrum of therapeutic areas, including cancer, diabetes, heart failure, rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, asthma, and many others, underlining its significant role in advancing medical treatments and improving patient outcomes across various disease states.

Products and Services

Ono Pharmaceutical's portfolio showcases a diverse range of therapeutic products and promising research areas:

• Opdivo Intravenous Infusion and Kyprolis Intravenous Injection - These are aimed at treating malignant tumors, highlighting the company's strength in oncology.
• Emend capsules/Proemend intravenous injections - Designed for managing chemotherapy-induced nausea and vomiting, providing crucial support for cancer patients.
• Demser capsules - Used for alleviating symptoms in patients with pheochromocytoma, a rare tumor of the adrenal gland tissue.
• Mektovi, Velexbru, and Braftovi capsules - Target malignant tumors, showcasing Ono Pharmaceutical's continued focus on cancer treatment.
• ADLUMIZ tablets - Developed for cancer cachexia, addressing the severe muscle and weight loss seen in cancer patients.
• Glactiv tablets and Forxiga tablets - These are oral medications for managing type 2 diabetes, reflecting the company’s contribution to chronic disease management.
• Onoact Intravenous Infusion - Used for tachyarrhythmia, a condition involving irregular heart rhythms.
• Opalmon tablets - Aimed at treating peripheral circulatory disorder.
• Coralan - This medication is prescribed for chronic heart failure, indicating Ono Pharmaceutical’s involvement in cardiovascular health.
• Orencia injections - Designed for rheumatoid arthritis, this product showcases the company's investment in autoimmune diseases.
• Rivastach patches - Developed for Alzheimer's disease, reflecting Ono Pharmaceutical’s commitment to neurodegenerative diseases.
• Ongentys tablets - Used for Parkinson's disease, further demonstrating the company's focus on neurological disorders.
• Additional Products: The range extends to treatments for dialysis patients, overactive bladder, bronchial asthma, allergic rhinitis, joint function improvement, and osteoporosis. This diverse portfolio underscores Ono Pharmaceutical's broad engagement across various therapeutic categories.

In addition to its available products, Ono Pharmaceutical is deeply invested in developing treatments for a wide array of conditions including various cancers, acute myeloid leukemia, solid tumors, myelodysplastic syndrome, melanoma, T-cell lymphoma, tachyarrhythmia, pemphigus, scleroderma, seizures, diabetic polyneuropathy, neurodegenerative diseases, autoimmune diseases, narcolepsy, and thrombosis. These efforts epitomize the company's dedication to pioneering in unmet medical needs and propelling healthcare forward.